-
Posted by
Two Blokes May 11 -
Filed in
Stock
-
11 views
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches. Is the stock cheap enough to buy the recent dip in the shares?
